Advances in Liposomal Drug Delivery Systems: Applications in Oncology, Infectious Diseases, and Beyond

*Vikrant Gupta, ¹Namrata Sharma
*Research Scholar, Shri Ramdeobaba College of Pharmacy, Jabalpur
¹Research Scholar, Shri Ramdeobaba College of Pharmacy, Jabalpur

Expand for Article Information

Authors: Vikrant Gupta, Namrata Sharma

Journal: Pexacy International Journal of Pharmaceutical Science

Volume/Issue: Volume 2, Issue 5

Page Range: 1-11

Publication Date: 08/05/2023

Contact: vikrant.gupta79@gmail.com

Abstract- Liposomal drug delivery systems have emerged as a transformative technology in the realm of pharmacology, offering targeted drug delivery across a wide range of medical conditions. This review article provides a comprehensive overview of the advancements in liposomal formulations specifically designed for the treatment of cardiovascular diseases, neurological disorders, and autoimmune diseases. It discusses various technologies and approaches that have been developed to improve therapeutic outcomes and patient compliance. The review also delves into the challenges and future prospects of liposomal drug delivery systems, including formulation stability, immunogenicity, and cost-effectiveness. Ongoing research and technological advancements are expected to further optimize these systems, revolutionizing the field of pharmacology and improving patient outcomes across various medical disciplines.

Keywords- Liposomal Drug Delivery, Targeted Therapy, Cardiovascular Diseases, Neurological Disorders, Autoimmune Diseases, Pharmacokinetics, Nanotechnology, Formulation Stability, Immunogenicity, Cost-effectiveness.

Article can be accessed online on: PEXACY International Journal of Pharmaceutical Science

*Corresponding Author- vikrant.gupta79@gmail.com

Update: Received on 01/05/2023; Accepted; 06/05/2023, Published on; 08/05/2023

Advances in Liposomal Formulations for Targeted Cancer Therapy

Liposomes in Chemotherapy

Liposomal drug delivery systems have revolutionized the field of oncology by enhancing the therapeutic index of chemotherapeutic agents. Traditional chemotherapy often suffers from poor bioavailability and systemic toxicity. Liposomal formulations encapsulate chemotherapeutic agents, thereby improving their pharmacokinetics and biodistribution. This encapsulation allows for targeted delivery to tumor cells while minimizing damage to healthy tissues. Liposomes have been particularly effective in the delivery of doxorubicin, a commonly used chemotherapeutic agent. The liposomal formulation of doxorubicin has shown improved therapeutic outcomes in various types of cancer, including breast and ovarian cancer (Park et al., 2004).

Immunoliposomes in Cancer Immunotherapy

The advent of immunotherapy has opened new avenues for cancer treatment. Immunoliposomes, a subclass of liposomes, have been engineered to carry immunotherapeutic agents like monoclonal antibodies. These immunoliposomes target specific antigens on cancer cells, thereby enhancing the specificity and efficacy of immunotherapy. This targeted approach has been particularly beneficial in the treatment of hematological malignancies, where conventional therapies often fall short (Kefalides, 1998).

Liposomes in Combination Therapies

The use of liposomes is not limited to monotherapy; they have also been employed in combination therapies. For instance, liposomal formulations have been developed to co-deliver chemotherapeutic agents and siRNA, offering a synergistic effect that enhances the overall therapeutic efficacy. This approach has shown promise in preclinical studies for the treatment of multidrug-resistant tumors, thereby addressing one of the major challenges in cancer therapy.

Challenges and Future Directions

While liposomal drug delivery systems offer numerous advantages, they are not without challenges. Issues such as stability, scalability, and cost-effectiveness need to be addressed for widespread clinical adoption. Moreover, the development of stimuli-responsive liposomes, which can release their payload in response to specific triggers like pH or temperature, is an area of active research. These advancements are expected to further optimize the therapeutic outcomes of liposomal formulations in cancer therapy.

Liposomal Drug Delivery Systems in Infectious Diseases

Liposomal Antibiotics in Bacterial Infections

The application of liposomal drug delivery systems extends beyond oncology to the realm of infectious diseases. Antibiotic resistance is a growing concern, and liposomal formulations offer a promising avenue for combating this issue. Liposomal antibiotics have been developed to improve the pharmacokinetics and biodistribution of antibiotics, thereby enhancing their therapeutic efficacy. For instance, liposomal formulations of antibiotics have shown promise in treating bacterial infections, including those caused by drug-resistant strains (Mr. Sadanand G Bondre et al., 2023).

Liposomal Vaccines in Viral Infections

Viral infections, such as influenza and COVID-19, have also been targeted using liposomal formulations. Liposomal vaccines encapsulate viral antigens or genetic material, thereby enhancing their stability and immunogenicity. These formulations have shown promise in preclinical and clinical studies, particularly in the context of lower respiratory tract viral infections (Attia et al., 2021).

Liposomes in Parasitic Diseases

Liposomal formulations have also been explored in the treatment of parasitic diseases like malaria. These formulations encapsulate antimalarial drugs, enhancing their bioavailability and therapeutic efficacy. Modeling studies have shown that liposomal systems can effectively distribute diprotic basic drugs, offering new perspectives on malaria nanotherapy (Moles et al., 2019).

Liposomes in Antisense Oligonucleotide Delivery

The versatility of liposomes extends to the delivery of antisense oligonucleotides, which are short DNA or RNA strands that can bind to specific mRNA molecules, thereby inhibiting gene expression. Liposomal formulations have been developed to deliver antisense oligonucleotides for various therapeutic areas, including infectious diseases (Gupta et al., 2023).

Challenges and Future Prospects

Despite the promising applications of liposomal drug delivery systems in infectious diseases, challenges such as formulation stability, immunogenicity, and cost-effectiveness remain. Ongoing research aims to address these issues and optimize the therapeutic outcomes of liposomal formulations in the treatment of infectious diseases (Gu et al., 2023).

Liposomal Drug Delivery Systems in Cardiovascular Diseases

Liposomes in Atherosclerosis Management

Cardiovascular diseases (CVDs) remain a leading cause of mortality globally, and atherosclerosis is a significant contributor to the development of CVDs. Liposomal formulations have been developed to encapsulate anti-atherosclerotic agents, thereby enhancing their therapeutic efficacy. For instance, liposomal formulations have shown promise in delivering statins directly to atherosclerotic plaques, thereby reducing systemic side effects and improving the therapeutic index (Yang et al., 2022).

Liposomal Antioxidants in Oxidative Stress

Oxidative stress plays a crucial role in the pathogenesis of cardiovascular diseases, particularly in conditions like myocardial infarction and hypertension. Liposomal antioxidants have been developed to scavenge reactive oxygen species, thereby mitigating oxidative stress and its associated complications. These formulations have shown promise in preclinical studies, particularly in the context of ischemia-reperfusion injury (Suntres & Omri, 2006).

Liposomes in Antiplatelet Therapy

Antiplatelet therapy is essential in the management of cardiovascular diseases to prevent thrombotic events. Liposomal formulations have been developed to deliver antiplatelet agents like aspirin and clopidogrel. These formulations offer a controlled release mechanism, thereby enhancing the therapeutic efficacy and reducing the risk of bleeding complications (Begum, 2019).

Liposomes in Stent and Balloon Applications

The use of stents and balloons in cardiovascular interventions has been revolutionized by the incorporation of liposomal drug delivery systems. These systems have been employed to deliver antiproliferative agents, thereby reducing the risk of restenosis post-angioplasty. The integration of liposomal formulations in stents and balloons has shown promise in improving long-term outcomes in patients undergoing cardiovascular interventions (Ng et al., 2022).

Challenges and Future Prospects

While liposomal drug delivery systems offer numerous advantages in the management of cardiovascular diseases, challenges such as formulation stability, immunogenicity, and cost-effectiveness remain. Ongoing research aims to address these issues and optimize the therapeutic outcomes of liposomal formulations in the treatment of cardiovascular diseases (Skourtis et al., 2020).

Liposomal Drug Delivery Systems in Neurological Disorders

Liposomal Formulations in Alzheimer’s Disease

Alzheimer’s disease (AD) is a neurodegenerative disorder that has been a focus of intense research in recent years. Liposomal formulations have been developed to encapsulate drugs like resveratrol, which have shown promise in mitigating the symptoms of AD. These formulations aim to improve the bioavailability of resveratrol and facilitate its transport across the blood-brain barrier, thereby enhancing its therapeutic efficacy in AD (Németh et al., 2020).

Liposomes in Parkinson’s Disease

Parkinson’s disease (PD) is another neurodegenerative disorder that has been targeted using liposomal drug delivery systems. Multi-functionalized liposomes have been developed to encapsulate drugs like levodopa, which are commonly used in the treatment of PD. These formulations aim to improve the pharmacokinetics and biodistribution of levodopa, thereby enhancing its therapeutic efficacy in PD (Rodà et al., 2023).

Liposomal Antipsychotics in Schizophrenia

Schizophrenia is a complex psychiatric disorder that often requires long-term medication. Liposomal formulations have been developed to encapsulate antipsychotic drugs, thereby improving their pharmacokinetics and reducing systemic side effects. These formulations have shown promise in preclinical studies, particularly in the context of long-term medication adherence (Sarmad, 2020).

Liposomes in Epilepsy Management

Epilepsy is a neurological disorder characterized by recurrent seizures. Liposomal formulations have been developed to encapsulate antiepileptic drugs, thereby improving their pharmacokinetics and reducing systemic side effects. These formulations have shown promise in preclinical studies, particularly in the context of drug-resistant epilepsy (Cardoso et al., 2022).

Challenges and Future Prospects

While liposomal drug delivery systems offer numerous advantages in the management of neurological disorders, challenges such as formulation stability, immunogenicity, and cost-effectiveness remain. Ongoing research aims to address these issues and optimize the therapeutic outcomes of liposomal formulations in the treatment of neurological disorders (Agnihotri et al., 2022).

Liposomal Drug Delivery Systems in Autoimmune Diseases

Liposomes in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints. Liposomal formulations have been developed to encapsulate drugs like methotrexate, which is a cornerstone in the treatment of RA. These formulations aim to improve the bioavailability of methotrexate and target inflamed joints, thereby enhancing its therapeutic efficacy in RA (Rajitha et al., 2017).

Liposomes in Psoriasis

Psoriasis is an autoimmune skin disorder characterized by red, itchy, and scaly patches. Liposomal formulations have been developed to encapsulate drugs like cyclosporine A, which are commonly used in the treatment of psoriasis. These formulations aim to improve the pharmacokinetics and biodistribution of cyclosporine A, thereby enhancing its therapeutic efficacy in psoriasis (Czogalla, 2009).

Liposomes in Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multiple organ systems. Liposomal formulations have been developed to encapsulate immunosuppressive agents, thereby improving their pharmacokinetics and reducing systemic side effects. These formulations have shown promise in preclinical studies, particularly in the context of long-term medication adherence (Tran & Amiji, 2015).

Liposomes in Multiple Sclerosis

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. Liposomal formulations have been developed to encapsulate drugs like interferon-beta, thereby improving their pharmacokinetics and reducing systemic side effects. These formulations have shown promise in preclinical studies, particularly in the context of drug-resistant MS (Li et al., 2022).

Challenges and Future Prospects

While liposomal drug delivery systems offer numerous advantages in the management of autoimmune diseases, challenges such as formulation stability, immunogenicity, and cost-effectiveness remain. Ongoing research aims to address these issues and optimize the therapeutic outcomes of liposomal formulations in the treatment of autoimmune diseases (Neupane et al., 2020).

Conclusion

The advent of liposomal drug delivery systems has revolutionized the field of pharmacology, offering a versatile platform for targeted drug delivery across a myriad of medical conditions. From oncology to infectious diseases, cardiovascular ailments to neurological disorders, and even autoimmune diseases, liposomal formulations have shown promise in enhancing therapeutic efficacy while minimizing systemic side effects (Liu et al., 2022).

The future of liposomal drug delivery systems appears to be bright, with ongoing research focusing on overcoming existing challenges such as formulation stability, immunogenicity, and cost-effectiveness. Advances in nanotechnology and materials science are expected to contribute to the development of more stable and efficient liposomal formulations. Moreover, the integration of active targeting mechanisms and stimuli-responsive release systems is likely to further optimize the therapeutic outcomes of these formulations (Fathi & Oyelere, 2016).

In the realm of ocular therapy, novel liposomal delivery systems are being developed to improve the bioavailability and therapeutic efficacy of drugs for conditions like glaucoma and age-related macular degeneration. These advancements could potentially revolutionize the management of ocular diseases, which have long been plagued by issues related to drug delivery and patient compliance (Bhattacharjee et al., 2019).

Furthermore, the application of liposomal drug delivery systems is not limited to human medicine alone. Veterinary oncology is also benefiting from these advancements, with liposomal formulations being developed for the targeted delivery of anticancer agents in animals. This opens up new avenues for improving the quality of life and survival rates in veterinary patients (Lainetti et al., 2020).

It is also worth noting that liposomal drug delivery systems have shown promise in the management of AIDS, with formulations being developed for the targeted delivery of antiretroviral drugs. These advancements could potentially revolutionize the management of this global pandemic, offering new hope for millions of patients worldwide (Asl et al., 2023).

In conclusion, liposomal drug delivery systems offer a versatile and efficient platform for targeted drug delivery, with applications spanning across various medical disciplines. Ongoing research and technological advancements are expected to further optimize these systems, thereby revolutionizing the field of pharmacology and improving patient outcomes across a wide range of medical conditions.

References

1. Park, J. W., Benz, C. C., & Martin, F. J. (2004). Future directions of liposome- and immunoliposome-based cancer therapeutics. Seminars in Oncology, 31(6 Suppl 13), 196–205.
2. Kefalides, P. T. (1998). New methods for drug delivery. Annals of Internal Medicine, 128(12 Pt 1), 1053–1055.
3. Mr. Sadanand G Bondre, Mr. Suraj B Rathod, Dr. Nitin B. Kohle, & Khan, M. N. (2023). Liposomal antibiotics for the treatment of infectious diseases. International Journal of Advanced Research in Science, Communication and Technology, 328–343.
4. Attia, M. A., Essa, E. A., Elebyary, T. T., Faheem, A. M., & Elkordy, A. A. (2021). Brief on recent application of liposomal vaccines for lower respiratory tract viral infections: From influenza to COVID-19 vaccines. Pharmaceuticals (Basel, Switzerland), 14(11), 1173.
5. Moles, E., Kavallaris, M., & Fernàndez-Busquets, X. (2019). Modeling the distribution of diprotic basic drugs in liposomal systems: Perspectives on malaria nanotherapy. Frontiers in Pharmacology, 10, 1064.
6. Gupta, R., Salave, S., Rana, D., Karunakaran, B., Butreddy, A., Benival, D., & Kommineni, N. (2023). Versatility of liposomes for antisense oligonucleotide delivery: A special focus on various therapeutic areas. Pharmaceutics, 15(5).
7. Gu, W., Andrews, G. P., & Tian, Y. (2023). Recent Clinical Successes in liposomal nanomedicines. International Journal of Drug Discovery and Pharmacology, 52–59.
8. Yang, F., Xue, J., Wang, G., & Diao, Q. (2022). Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in Pharmacology, 13, 999404.
9. Suntres, Z. E., & Omri, A. (2006). The role of liposomal antioxidants in oxidative stress. In Nanocarrier Technologies (pp. 191–205). Springer Netherlands.
10. Begum, S. G. (2019). Various novel drug delivery systems in treatment of cardiovascular diseases. Indian Journal of Pharmaceutical and Biological Research, 7(04), 01–04.
11. Ng, J. C. K., Toong, D. W. Y., Ow, V., Chaw, S. Y., Toh, H., Wong, P. E. H., Venkatraman, S., Chong, T. T., Tan, L. P., Huang, Y. Y., & Ang, H. Y. (2022). Progress in drug-delivery systems in cardiovascular applications: stents, balloons and nanoencapsulation. Nanomedicine (London, England), 17(5), 325–347.
12. Skourtis, D., Stavroulaki, D., Athanasiou, V., Fragouli, P. G., & Iatrou, H. (2020). Nanostructured polymeric, liposomal and other materials to control the drug delivery for cardiovascular diseases. Pharmaceutics, 12(12), 1160.
13. Németh, Z., Pallagi, E., Dobó, D. G., & Csóka, I. (2020, December 1). How could QbD address the R&D challenges of ‘nose-to-brain’ liposomal resveratrol formulations? The 1st International Electronic Conference on Pharmaceutics. International Electronic Conference on Pharmaceutics, Sciforum.net.
14. Rodà, F., Picciolini, S., Mangolini, V., Gualerzi, A., Seneci, P., Renda, A., Sesana, S., Re, F., & Bedoni, M. (2023). Raman Spectroscopy characterization of multi-functionalized liposomes as drug-delivery systems for neurological disorders. Nanomaterials (Basel, Switzerland), 13(4).
15. Sarmad, A. (2020). Utilization of polymer and Lipid-Based Drug delivery systems in treatment of neurological disorders- a mini review. International Journal of Medical Science and Diagnosis Research, 4(11).
16. Cardoso, R. V., Pereira, P. R., Freitas, C. S., & Paschoalin, V. M. F. (2022). Trends in drug delivery systems for natural bioactive molecules to treat health disorders: The importance of nano-liposomes. Pharmaceutics, 14(12).
17. Agnihotri, T. G., Jadhav, G. S., Sahu, B., & Jain, A. (2022). Recent trends of bioconjugated nanomedicines through nose-to-brain delivery for neurological disorders. Drug Delivery and Translational Research, 12(12), 3104–3120.
18. Rajitha, P., Biswas, R., Sabitha, M., & Jayakumar, R. (2017). Methotrexate in the treatment of psoriasis and rheumatoid arthritis: Mechanistic insights, current issues and novel delivery approaches. Current Pharmaceutical Design, 23(24), 3550–3566.
19. Czogalla, A. (2009). Oral cyclosporine A–the current picture of its liposomal and other delivery systems. Cellular & Molecular Biology Letters, 14(1), 139–152.
20. Tran, T.-H., & Amiji, M. M. (2015). Targeted delivery systems for biological therapies of inflammatory diseases. Expert Opinion on Drug Delivery, 12(3), 393–414.
21. Li, H., Yang, Y.-G., & Sun, T. (2022). Nanoparticle-based drug delivery systems for induction of tolerance and treatment of autoimmune diseases. Frontiers in Bioengineering and Biotechnology, 10, 889291.
22. Neupane, Y. R., Mahtab, A., Siddiqui, L., Singh, A., Gautam, N., Rabbani, S. A., Goel, H., & Talegaonkar, S. (2020). Biocompatible nanovesicular drug delivery systems with targeting potential for autoimmune diseases. Current Pharmaceutical Design, 26(42), 5488–5502.
23. Liu, P., Chen, G., & Zhang, J. (2022). A review of liposomes as a drug delivery system: Current status of approved products, regulatory environments, and future perspectives. Molecules (Basel, Switzerland), 27(4), 1372.
24. Fathi, S., & Oyelere, A. K. (2016). Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice? Future Medicinal Chemistry, 8(17), 2091–2112.
25. Bhattacharjee, A., Das, P. J., Adhikari, P., Marbaniang, D., Pal, P., Ray, S., & Mazumder, B. (2019). Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery. European Journal of Ophthalmology, 29(1), 113–126.
26. Lainetti, P. de F., Zuliani, F., Leis-Filho, A. F., Fonseca Alves, R. H., & Fonseca-Alves, C. E. (2020). Controlled drug delivery vehicles in veterinary oncology: State-of-the-art and future directions. Processes (Basel, Switzerland), 8(5), 541.
27. Asl, F. D., Mousazadeh, M., Taji, S., Bahmani, A., Khashayar, P., Azimzadeh, M., & Mostafavi, E. (2023). Nano drug-delivery systems for management of AIDS: liposomes, dendrimers, gold and silver nanoparticles. Nanomedicine (London, England), 18(3), 279–302.